News and Events

Congratulations to our faculty whose abstracts and research were presented at the annual ASH meeting:

Lee, S., Yin, C., Ayello, J., Morris, E., van de Ven, C., and Cairo, M.S. Ruxolitinib significantly prolongs survival in both a primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL) xenograft NSG mouse model: ruxolitinib may be a potential adjuvant agent in the treatment of PMBL and of HL. Accepted for presentation, American Society of Hematology, 2015. Blood ASH Annual Meeting Abstracts, #2732.

Tiwari, A. Rolland, D.C.M., Elmacken, M., Ayello, J., van de Ven, C., Basrur, V., Conlon, K., Fermin, D., Barth, M.J., Klein, C., Elenitoba-Johnson, K., Lim, M.S., and Cairo, M.S. Comparative phosphoproteomics sudy between obinutuzumab (GA101) vs. rituximab (RTX) against RTX sensitive/resistant Burkitt lymphoma (BL): Differentially phosphorylated B cel receptor, Fc-gamma receptor, phagocytosis and natural killer cell-mediated cytotoxicity signaling pathway proteins. Accepted for presentation, American Society of Hematology, 2015. Blood ASH Annual Meeting Abstracts, #1550.

Lee, S., Yin, C., Ayello, J., Morris, E., van de Ven, C., and Cairo, M.S. Downregulation of DLEU1 significantly shortened survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL. Accepted for presentation, American Society of Hematology, 2015. Blood ASH Annual Meeting Abstracts, #3656.

Hochberg, J.C., Oesterheld, J., Militano, O., Harrison, L., and Cairo, M.S. A pilot study of mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults (CAYA) with refractory/relapsed acute leukemia. Accepted for presentation American Society of Hematology, 2015. Blood ASH Annual Meeting Abstracts, #2499.

Chu, Y., Lee, F., Ayello, J., Hang, B., Zhang, M., Wong, H.C., Lee, D.A., and Cairo, M.S. Therapeutic effects of Alt-803, an IL-15 superagonist, in combination with anti-CD20 chimeric antigen receptor modified expanded natural killer cells against pediatric Burkitt lymphoma (BL). Accepted for presentation, American Society of Hematology, 2015. Blood ASH Annual Meeting Abstracts, #3085.